Product Description
The 1A8-CP129 monoclonal antibody is a recombinant Fc-engineered chimeric version of the original 1A8 antibody. The variable domain sequences are identical to the original 1A8 hybridoma-derived antibody, but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. 1A8-CP129 has been demonstrated to have superior Ly6G targeted cell depletion compared to the original hybridoma-derived antibody in-vivo. This antibody has an effector function competent Fc domain allowing for activation of Fcgamma receptors (FcgammaRs) to trigger antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. Species-matched chimeric antibodies result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The 1A8-CP129 monoclonal antibody reacts with mouse Ly6G, a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Ly6G is expressed differentially during development by cells in the myeloid lineage including monocytes, macrophages, granulocytes, and neutrophils. Monocytes typically express Ly6G transiently during development while mature granulocytes and peripheral neutrophils retain expression making Ly6G a good cell surface marker for these populations. Unlike the RB6-8C5 antibody, the 1A8-CP129 antibody reacts specifically with mouse Ly6G with no reported cross reactivity with mouse Ly6C.
* VAT and shipping costs not included. Errors and price changes excepted
